{"id":9038,"date":"2026-01-20T17:21:37","date_gmt":"2026-01-20T16:21:37","guid":{"rendered":"https:\/\/www.kedrion.it\/?post_type=news&#038;p=9038"},"modified":"2026-01-20T17:24:32","modified_gmt":"2026-01-20T16:24:32","slug":"fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases","status":"publish","type":"news","link":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/","title":{"rendered":"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases"},"content":{"rendered":"\n<!--more-->\n\n\n\n<p><strong>Kedrion, one of the FAB\u201113<\/strong>, the thirteen historic Made in Italy pharmaceutical companies belonging to&nbsp;<strong>Farmindustria<\/strong>, is part of a supply chain recognized for its industrial continuity and a development model oriented toward innovation, with significant impacts on the national system.<br>The new&nbsp;<strong>Edison Foundation Report on the FAB\u201113<\/strong>&nbsp;confirms the solidity of the Italian pharmaceutical model:&nbsp;<strong>the updated 2024 data<\/strong>, highlighting&nbsp;<strong>the growth of exports, revenues, investments, and employment<\/strong>, show how the sector continues to contribute substantially to Italy\u2019s competitiveness in global markets.<\/p>\n\n\n\n<p>The&nbsp;<strong>FAB\u201113<\/strong>&nbsp;remain a strategic asset thanks to the 2024 growth in&nbsp;<strong>exports (+16%)<\/strong>,&nbsp;<strong>revenues (+12%)<\/strong>,&nbsp;<strong>investments (+21%)<\/strong>, and&nbsp;<strong>skilled employment (+2% in Italy)<\/strong>. Together, these results underscore the Italian model\u2019s ability to combine strong territorial roots with an international vision.<\/p>\n\n\n\n<p>In 2024,&nbsp;<strong>the production value<\/strong>&nbsp;of multinational and Italian groups affiliated with Farmindustria&nbsp;<strong>totaled \u20ac56.1 billion<\/strong>, marking an 87% increase compared to 2016, while&nbsp;<strong>exports reached \u20ac53.8 billion<\/strong>, a 152% rise since 2016. Particularly significant was the growth in exports of high\u2011technology pharmaceutical products, which increased by 193%.&nbsp;<strong>Total investments reached \u20ac4 billion<\/strong>, including \u20ac2.3 billion allocated to Research and Development (R&amp;D) and \u20ac1.7 billion to manufacturing activities (a 38% increase since 2016).&nbsp;<strong>Sector employment rose to 67,000 jobs<\/strong>&nbsp;(+12% compared to 2016).<\/p>\n\n\n\n<p>Within this context,&nbsp;<strong>Kedrion provides a specific contribution in the field of rare, ultra\u2011rare, and serious diseases<\/strong>, an area requiring advanced expertise, industrial continuity, and a strong sense of responsibility toward patient communities with complex clinical needs. Through the production of plasma\u2011derived therapies, the pursuit of new therapeutic solutions, and collaborations with academic and clinical centers, the company works to make essential therapies available &#8211; often unique or difficult to replace.<\/p>\n\n\n\n<p>This&nbsp;<strong>social commitment<\/strong>&nbsp;is supported by a&nbsp;<strong>production model firmly rooted in Italy<\/strong>, enabling investment in expertise, technologies, and scientific partnerships. The result is a contribution that combines&nbsp;<strong>industrial value with value for people\u2019s health<\/strong>.<\/p>\n","protected":false},"featured_media":9039,"template":"","categories_news":[45],"class_list":["post-9038","news","type-news","status-publish","has-post-thumbnail","hentry","categories_news-corporate-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases - Kedrion Biopharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases - Kedrion Biopharma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Kedrion Biopharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-20T16:24:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"587\" \/>\n\t<meta property=\"og:image:height\" content=\"439\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/\",\"url\":\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/\",\"name\":\"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases - Kedrion Biopharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.kedrion.it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg\",\"datePublished\":\"2026-01-20T16:21:37+00:00\",\"dateModified\":\"2026-01-20T16:24:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#primaryimage\",\"url\":\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg\",\"contentUrl\":\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg\",\"width\":587,\"height\":439},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.kedrion.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.kedrion.it\/news-archive\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.kedrion.it\/#website\",\"url\":\"https:\/\/www.kedrion.it\/\",\"name\":\"Kedrion Biopharma\",\"description\":\"Plasma-Derived Medicinal Products | Keep Life Flowing\",\"publisher\":{\"@id\":\"https:\/\/www.kedrion.it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.kedrion.it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.kedrion.it\/#organization\",\"name\":\"Kedrion S.p.A.\",\"url\":\"https:\/\/www.kedrion.it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg\",\"contentUrl\":\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg\",\"width\":1772,\"height\":870,\"caption\":\"Kedrion S.p.A.\"},\"image\":{\"@id\":\"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases - Kedrion Biopharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/","og_locale":"en_US","og_type":"article","og_title":"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases - Kedrion Biopharma","og_url":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/","og_site_name":"Kedrion Biopharma","article_modified_time":"2026-01-20T16:24:32+00:00","og_image":[{"width":587,"height":439,"url":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/","url":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/","name":"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases - Kedrion Biopharma","isPartOf":{"@id":"https:\/\/www.kedrion.it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#primaryimage"},"image":{"@id":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg","datePublished":"2026-01-20T16:21:37+00:00","dateModified":"2026-01-20T16:24:32+00:00","breadcrumb":{"@id":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#primaryimage","url":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg","contentUrl":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2026\/01\/IMG_1548.jpg","width":587,"height":439},{"@type":"BreadcrumbList","@id":"https:\/\/www.kedrion.it\/en\/fab-13-kedrions-contribution-in-rare-and-ultrarare-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kedrion.it\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.kedrion.it\/news-archive\/"},{"@type":"ListItem","position":3,"name":"FAB 13: New results confirm the strength of the Italian pharmaceutical model. Kedrion\u2019s contribution in rare and ultra\u2011rare diseases"}]},{"@type":"WebSite","@id":"https:\/\/www.kedrion.it\/#website","url":"https:\/\/www.kedrion.it\/","name":"Kedrion Biopharma","description":"Plasma-Derived Medicinal Products | Keep Life Flowing","publisher":{"@id":"https:\/\/www.kedrion.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kedrion.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kedrion.it\/#organization","name":"Kedrion S.p.A.","url":"https:\/\/www.kedrion.it\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg","contentUrl":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg","width":1772,"height":870,"caption":"Kedrion S.p.A."},"image":{"@id":"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/news\/9038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/media\/9039"}],"wp:attachment":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/media?parent=9038"}],"wp:term":[{"taxonomy":"categories_news","embeddable":true,"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/categories_news?post=9038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}